Contrary to bacterial infection that can be treated with various antibiotics viral infection treatments are limited. Even if several treatments have been developed for specific virus infection, broad spectrum antivirals have not been developed yet Also, viruses are known to adapt to treatment and develop resistance, leading to therapeutic failure. Therefore, there is a constant need for new generation of first or best in class molecules that can be positioned in first line treatment or in combination with pre existing therapies.
A collection of 50 antiviral corrole based molecules has been synthesized and tested on a line of human and animal viruses. Some of these compounds display selectivity index of around 500 and good PK profile No acute toxicity has been detected in vivo. These compounds show good efficacy when used alone and
some also display synergistic action with gold standard and are active on resistant strains. They are also easy to synthesize in a one to two step reaction Upscaling
production up to 25 g is available.
MARKETS & APPLICATIONS
Pharmaceutical human & animal antivirals:
In vitro activity demonstrated on pox and herpes viruses infected cells - In vivo testing is currently in progress
UMR CNRS 6302 Institute of Molecular Chemistry of the University of Burgundy (ICMUB)
Two european patent applications (2017 November) and PCT extensions (2018 November)
+33 (0)6 31 10 21 21